Three-month follow-up with complete blood count and transaminases is required because of the risk of granulocytosis 42 and liver compromise with prolonged use.
Debe hacerse seguimiento trimestral con hemograma y transaminasas por riesgo de agranulocitosis 42 y compromiso hepático con el uso prolongado.